louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00454090: AZD8330 First Time in Man in Patients With Advanced Malignancies
Official title: A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Keywords: Advanced Malignancies
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-03-29
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies


Eligibility criteria: Inclusion Criteria:

* Cancer which is refractory to standard therapies, or no therapies exist;

Exclusion Criteria:

* Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start;
* Hasn't participated in investigation drug study within 30 days;
* Brain metastases/spinal cord compression unless treated and stable,
* Off steroids/anticonvulsants.

Primary outcomes:
measure: To assess safety and tolerability of AZD8330 in patient with advanced malignancies.
measure: Outcome variables: Adverse Events, Clinical Chemistry, Haematology, Urinalysis, Vital signs, MUGA scans/echocardiography, ECGs, Ophthalmologic examination, O2 saturation
Secondary outcomes:
measure: To determine the PK of AZD8330.
measure: To investigate possible PD/PK relationships
measure: To investigate effect of AZD8330 on pERK in PBMCs
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: Houston
country: United States
facility: Research Site
state: Texas
city: Oslo
country: Norway
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: Emerging Oncology Medical Science Director, MD
role: STUDY_DIRECTOR
References:
citation: Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9. doi: 10.1016/j.ejca.2013.01.013. Epub 2013 Feb 21.
Clinical trial NCT06168890: Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure.
Official title: Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2023-12-13
Enrollment: 195
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients suffering from prostate cancer with biochemical recovery of the disease during hormonal therapy who have undergone PET/CT with choline for restaging of the disease after primary treatment.

Brief summary: Several studies have shown that the PET/CT study with Choline is of great use in the restaging of patients with prostate cancer who present a recurrence of biochemical disease following primary treatment. Despite the large amount of literature in which the diagnostic accuracy of the method is highlighted in the identification of the recurrence of prostatic disease both in the case of local recurrence, lymph node recurrence and metastatic disease, there are to date no studies that evaluate whether PET /CT with choline may predict survival in patients radically treated for prostate cancer. The aim of the study is to evaluate the predictive role of choline PET/CT on the survival of patients with biochemical recovery of the disease during hormonal therapy.

This retrospective study will include adult patients affected by prostate cancer with biochemical recurrence of the disease following radical prostatectomy treatment and undergoing hormonal therapy who underwent, between 2004 and 2007, a PET/CT study with choline for the restaging of their disease.

The expected result is to establish how PET/CT with Choline can predict survival in patients who develop a biochemical recurrence of the disease during hormonal therapy. If this result is confirmed, PET/CT with Choline could be even more useful in the follow-up of patients radically treated for prostate cancer to plan the best therapeutic approach.


Eligibility criteria: Inclusion Criteria:

* patients who have been treated with radical prostatectomy;
* patients who present a progressive increase in PSA value during hormonal treatment.

Exclusion Criteria:

* patients\< 18 years

Primary outcomes:
measure: PET CT with choline on the survival of patients with biochemical recovery of prostate cancer
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00760890: Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation
Official title: Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Iron Deficiency
Keywords: Iron, breastfed infant
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Sponsor class: NIH
First posted: 2008-09-26
Enrollment: 171
Sex: ALL
Minimum age (years): 1
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Normal breastfed infants can develop iron deficiency by 6 months of age. This trial tested the hypothesis that regular provision of a source of iron beginning at 4 months of age improves iron status and could prevent iron deficiency. This was a prospective randomized trial involving breastfed infants. To be eligible, infants had to be predominantly breastfed (\<200 ml/day of formula) at 4 months of age. At 4 months infants were randomly assigned to one of two interventions or to control. The interventions consisted in the daily administration of medicinal iron in a dose of 7.5 mg (Medicinal Iron Group) or in the daily feeding of one jar of an iron-fortified cereal providing 7 mg of iron each day (Cereal Group). The control group received complementary foods chosen by he parents but no source of iron provided by the investigators. The interventions took place from 4 to 9 months. All infants were subsequently followed to 2 years of age.


Eligibility criteria: Inclusion Criteria:

* Predominantly breastfed (at 4 months) term infants

Exclusion Criteria:

* Not predominantly breastfed at 4 months
* Premature infants

Primary outcomes:
measure: Iron status
timeFrame: 3 times during the intervention
Secondary outcomes:
measure: Growth
timeFrame: At the end of intervention
measure: Tolerance (gastrointestinal)
timeFrame: During intervention
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: Fomon Infant Nutrition Unit
state: Iowa
Study officials:
affiliation: University of Iowa
name: Ekhard E Ziegler, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ziegler EE, Nelson SE, Jeter JM. Iron status of breastfed infants is improved equally by medicinal iron and iron-fortified cereal. Am J Clin Nutr. 2009 Jul;90(1):76-87. doi: 10.3945/ajcn.2008.27350. Epub 2009 May 20.
Clinical trial NCT04309890: Arabic Translation and Validation of the (Overactive Bladder Symptom Score) OABSS
Official title: Validating 7-items Overactive Bladder Symptom Score (OABSS) Through Arabic Linguistic Version
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Overactive Bladder
Lead sponsor: Mutah University
Sponsor class: OTHER
First posted: 2020-03-16
Enrollment: 235
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study has included 235 patients, 152 (62.9%) females and 83 (37.1%) males.

Brief summary: The English version of the Overactive Bladder Symptom Score (OABSS) questionnaire was translated to Arabic language. The questionnaire was validated by comparing the response to the questionnaire in a patient with Overactive Bladder (OAB) before and after providing treatment with antimuscarinics.


Eligibility criteria: Inclusion Criteria:

* More than 20 years
* Had three months history of overactive bladder symptoms (urgency with or without incontinence and associated with frequency and nocturia).

Exclusion Criteria:

* Active urinary tract infection.
* Predominant symptoms of urinary stress incontinence;
* Diabetes mellitus;
* Previous abdominal and pelvic (urological or gynecological gastrointestinal) surgery;
* Previous neurological disease.

Primary outcomes:
measure: development and validation of Arabic version of the Overactive Bladder Symptom Score (OABSS) questionnaire
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Karak
country: Jordan
facility: Mu'tah University
Study officials:
References:
citation: Sawaqed F, Suoub M. Validating 7-items Overactive Bladder Symptom Score (OABSS) through Arabic linguistic version. Sci Rep. 2021 Jan 12;11(1):661. doi: 10.1038/s41598-020-79974-9.
Clinical trial NCT00595790: Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
Official title: Phase 3 Study to Compare a Rapid Immunization Regime With the Standard Regime of IC51 as Vaccine for Japanese Encephalitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Japanese Encephalitis
Lead sponsor: Valneva Austria GmbH
Sponsor class: INDUSTRY
First posted: 2008-01-16
Enrollment: 374
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51 (JE-PIV) in healthy subjects aged \> or = 18 years

Detailed description: This is a multicenter, observer blinded, controlled, randomized phase 3 study. The study population consists of healthy male and female volunteers, aged at least 18 years.

Approximately 375 volunteers will be enrolled at approximately 2 to 3 sites.

Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Written informed consent obtained prior to study entry

Exclusion Criteria:

* History of clinical manifestation of any flavivirus infection
* History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis)
* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine
* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy
* A family history of congenital or hereditary immunodeficiency
* History of autoimmune disease
* Any acute infections within 4 weeks prior to enrollment
* Infection with HIV, Hepatitis B or Hepatitis C
* Pregnancy, lactation or unreliable contraception in female subjects

Primary outcomes:
measure: SCR (Seroconversion Rate) at Day 56
timeFrame: day 56
Secondary outcomes:
measure: SCR at Day 10, 28 and 35
timeFrame: Day 10, 28 and 35
measure: GMT at Day 10, 28, 35 and 56
timeFrame: Day 10, 28, 35 and 56
measure: Safety
timeFrame: Study duration
Other outcomes:
Locations:
Study officials:
affiliation: Valneva Austria GmbH
name: Susanne Eder, Mag.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02151890: Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
Official title: Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure (POF)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Premature Ovarian Failure
Keywords: POF
ESS
stem cell
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2014-06-02
Enrollment: 10
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Out of 112 high risk patients for Premature Ovarian Failure (POF), diagnosis was established in 10 cases.

ESS cut off point for menstruation and pregnancy was 6.

Detailed description: Out of 112 high risk patients for POF, diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by immubohistchemical (IH) staining by stem cell marker OCT4. IH expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Score (ESS).

After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).

These cases were of ESS 5 and 6.

Eligibility criteria: Inclusion Criteria:

* Post-menarche female less than 40 years old.
* Normal karyotyping female.
* Primary ovarian failure females
* Follicle-stimulating hormone (FSH) more than or equal to 20 IU/L.
* Agree to sign the designed consent for the study.

Exclusion Criteria:

* Autoimmune diseases.
* Breast cancer, ovarian cancer.
* Hypersensitivity to any Gonadotropin-releasing hormone (GnRH) analogs.
* Those with major medical problems such as malignancy, hepatitis, etc.

Primary outcomes:
measure: Pregnancy
timeFrame: 104 weeks
Secondary outcomes:
measure: Menstruation
timeFrame: 104 weeks
Other outcomes:
measure: Ovulation
timeFrame: 104 weeks
Locations:
city: Cairo
country: Egypt
facility: Al Azhar University
Study officials:
affiliation: Al-Azhar University
name: Mahmoud Edessy, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Cairo University
name: Hala N Hosni, Professor
role: STUDY_CHAIR
affiliation: Al-Azhar University
name: Yehia Wafa, Professor
role: STUDY_CHAIR
affiliation: Al-Azhar University
name: Yousef Shady, MD
role: STUDY_CHAIR
affiliation: Al-Azhar University
name: Sayed Bakri, MD
role: STUDY_CHAIR
affiliation: Al-Azhar University
name: Medhat Kamel, Msc
role: STUDY_CHAIR
References:
Clinical trial NCT00855790: Comparison of Two Types of Biopsy Forceps for Obtaining Cold Biopsy Polypectomy for Small Sessile Colorectal Polyps Less Than 6 mm in Diameter
Official title: Comparison of Two Types of Biopsy Forceps for Obtaining Cold Biopsy Polypectomy for Small Sessile Colorectal Polyps Less Than 6 mm in Diameter
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Polyps
Keywords: evaluate the effectiveness of one bite polypectomy with the RJ3 biopsy forcep versus the RJ4 biopsy forcep
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2009-03-04
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the efficacy of the new RJ4 compare with the standard RJ3 biopsy forceps for performing polypectomy for small colorectal polyps.


Eligibility criteria: Inclusion Criteria:

* colon polyps less than 6 mm

Exclusion Criteria:

* no colon polyps

Primary outcomes:
measure: Complete endoscopic (visual) eradication of the polyp with the first forceps bite
timeFrame: one year
Secondary outcomes:
measure: Number of bites to completely visually eradicate the polyp if the polyp was not fully eradicated with the first forceps bite
timeFrame: one year
measure: Complete pathologic eradication of the polyp on the first forceps bite.
timeFrame: one year
measure: Correlate endoscopic with pathologic eradication
timeFrame: one year
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Shands Endocopy Center
state: Florida
Study officials:
affiliation: University of Florida
name: Peter Draganov, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Draganov PV, Chang MN, Alkhasawneh A, Dixon LR, Lieb J, Moshiree B, Polyak S, Sultan S, Collins D, Suman A, Valentine JF, Wagh MS, Habashi SL, Forsmark CE. Randomized, controlled trial of standard, large-capacity versus jumbo biopsy forceps for polypectomy of small, sessile, colorectal polyps. Gastrointest Endosc. 2012 Jan;75(1):118-26. doi: 10.1016/j.gie.2011.08.019.
Clinical trial NCT02714790: Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia
Official title: Ruolo Prognostico Della Malattia Minima Residua Nella Leucemia Mieloide Acuta
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Myeloid Leukemia
Minimal Residual Disease
Wilms Tumor
Keywords: Acute Myeloid Leukemia
Minimal Residual Disease
Wilms Tumor
Lead sponsor: A.O.U. Città della Salute e della Scienza
Sponsor class: OTHER
First posted: 2016-03-22
Enrollment: 281
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient with new diagnosis of acute myeloid leukemia treated with intensive chemotherapy

Brief summary: Study purpose is to assess the prognostic role of Minimal Residual Disease (defined as medullary expression of WT1 gene), performed at Baseline and during treatment according to clinical practice. MRD results will be relate to treatment outcome and survival analysis variables (Overall Survival, Disease Free Survival, Cumulative Incidence of Relapse)


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Acute Myeloid Leukemia
* Age \> 18 years
* Intensive chemotherapy as first line curative treatment
* Observation period: March 2004 - September 2014
* Bone marrow WT1 expression and Immunophenotyping by multi-parametric flow cytometry performed at baseline
* Written informed consent

Exclusion Criteria:

* Diagnosis of Acute Promyelocytic Leukemia
* Bone marrow WT1 expression and Immunophenotyping by multi-parametric flow cytometry NOT performed at baseline
* Patient ineligible to intensive chemotherapy

Primary outcomes:
measure: Response
timeFrame: +28 days after End of induction chemotherapy - Before Allogeneic Transplant, average of 3 to 6 months from beginning of therapy
Secondary outcomes:
measure: Disease Free Survival
timeFrame: +28 days after End of induction chemotherapy -Before Allogeneic Transplant, average of 3 to 6 months from beginning of therapy - +30 days after Allogeneic Transplant - Date of Relapse for at least 1 year (up to 10 years)
measure: Overall Survival
timeFrame: Date of last follow-up for at least 1 year (up to 10 years) or Death
measure: Cumulative Incidence of Relapse
timeFrame: Date of Allogeneic Transplant, Date of Relapse for at least 1 year (up to 10 years - assessed every 3 months), Date of last follow-up for at least 1 year (up to 10 years) or Death
Other outcomes:
Locations:
Study officials:
affiliation: AO Città della Salute e della Scienza di Torino
name: Ernesta Audisio, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Frairia C, Aydin S, Audisio E, Riera L, Aliberti S, Allione B, Busca A, D'Ardia S, Dellacasa CM, Demurtas A, Evangelista A, Ciccone G, Francia di Celle P, Nicolino B, Stacchini A, Marmont F, Vitolo U. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. Leuk Res. 2017 Oct;61:10-17. doi: 10.1016/j.leukres.2017.08.008. Epub 2017 Aug 30.
Clinical trial NCT05404490: Efficacy of Bupivacain Local Infiltration for the Management of Pain During Cesarean Section
Official title: Efficacy of Bupivacain Local Infiltration for the Management of Pain During Cesarean Section. Randomized, Single Blind, Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain, Postoperative
Keywords: Cesarean section
Postoperative Pain
Bupivacain
Lead sponsor: Saint Thomas Hospital, Panama
Sponsor class: OTHER
First posted: 2022-06-03
Enrollment: 202
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the effect of local administration of bupivacain in the cesarean section incision for postoperative pain control, using the visual analogue pain scale (VAS) and assessing the need for rescue analgesia after surgery.


Eligibility criteria: Inclusion Criteria:

* Gestational age ≥ 36 weeks
* Elective cesarean section
* Transverse segmental caesarean section Pfannenstiel type
* Spinal anesthesia
* Maternal age 18 to 45 years
* Any gravaparity
* Patient ASA I or II

Exclusion Criteria:

* Any patient who does not meet the inclusion criteria.
* Emergency cesarean section
* History of chronic or neuropathic pain
* Patient with cardiopulmonary disease
* Known allergies to the drugs used in the study
* Patient who does not wish to participate in the study

Primary outcomes:
measure: Post operative pain
timeFrame: 72 hours
Secondary outcomes:
measure: Need for rescue medication
timeFrame: 72 hours
Other outcomes:
Locations:
city: Panama
country: Panama
facility: Saint Thomas H
Study officials:
References:
Clinical trial NCT06499090: Mirtazapine for Acute and Chronic Post Mastectomy Pain
Official title: The Effect of Peri-operative Mirtazapine on Acute and Chronic Post Mastectomy Pain (prospective Randomized Controlled Study)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: EARLY_PHASE1
Conditions: Breast Cancer
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-07-12
Enrollment: 62
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Our aim in this study will be to investigate the effect of mirtazapine on acute post-mastectomy pain manifested by total morphine consumption in first 24 hours and VAS score at rest and movement (primary outcomes). chronic neuropathic pain using LANSS Pain Scale (Leeds Assessment of Neuropathic Signs and Symptoms) and to evaluate the quality of recovery using the quality of recovery-40scoring system(QoR-40) (secondary outcomes) following modified radical mastectomy for breast cancer.


Eligibility criteria: Inclusion Criteria:

female patients aged 20-70 years scheduled for modified radical mastectomy with axillary dissection for breast carcinoma

Exclusion Criteria:

* known allergy to the study drugs significant organ dysfunction drug or alcohol abuse epilepsy patients with chronic pain or regularly receiving analgesics any psychiatric illness that would interfere with the perception and the assessment of pain

Primary outcomes:
measure: The cumulative postoperative 24 h morphine consumption
timeFrame: 24 hours
Secondary outcomes:
measure: The visual analogue score of pain intensity
timeFrame: 24 hours
measure: The quality of recovery-40 questionnaire
timeFrame: 24 hours
measure: Assessment of sedation level
timeFrame: 24 hours
measure: Assessment of chronic pain
timeFrame: 6 months
measure: Depression score
timeFrame: 6 months
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: south Egypt Cancer Institute Assiut University
Study officials:
References: